University of Washington: Lymphoma, Non-Hodgkin trials

The registry lists 13 Lymphoma, Non-Hodgkin studies with University of Washington as lead sponsor. 0 are open to participants now and 10 have results posted.

Phase 1 4Phase 2 12(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin LymphomaCompletedNCT05169658Phase 2Results posted
• Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell LymphomaActive, not recruitingNCT04257578Phase 1/2Results posted
• Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic MalignanciesCompletedNCT04205409Phase 2Results posted
• Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative DiseasesTerminatedNCT03498612Phase 2Results posted
• Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell LymphomaTerminatedNCT03401853Phase 2Results posted
• Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaCompletedNCT03023046Phase 2Results posted
• Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin LymphomaCompletedNCT02207062Phase 2Results posted
• Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ LymphomaActive, not recruitingNCT01703949Phase 2Results posted
• Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple MyelomaCompletedNCT01110135Phase 2Results posted
• Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell LymphomaCompletedNCT00601718Phase 1/2Results posted
• Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic LeukemiaCompletedNCT03991884Phase 1
• Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell LymphomaWithdrawnNCT02729961Phase 1/2
• Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaWithdrawnNCT02538926Phase 2